NCT07502027

A Clinical Study of Iparomlimab and Tuvonralimab Combined With SOX Following Heterogeneous Radiotherapy as First-line Treatment for Unresectable Locally Advanced or Metastatic HER2-negative Gastric or Gastroesophageal Junction Adenocarcinoma

A Multicenter, Single-arm, Exploratory Clinical Study of Iparomlimab and Tuvonralimab Combined With SOX Following Heterogeneous Radiotherapy as First-line Treatment for Unresectable Locally Advanced or Metastatic HER2-negative Gastric or Gastroesophageal Junction Adenocarcinoma

• Status: Not Yet Recruiting
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 55 (estimated)
• Sponsor: Huazhong University of Science and Technology · Academic / Other
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

This study is a domestic, multicenter, single-arm clinical trial designed to evaluate the efficacy and safety of heterogeneous radiotherapy (high and low dose) sequenced with iparomlimab and tuvonralimab plus SOX as a first-line treatment for unresectable locally advanced or metastatic HER2-negative gastric or gastroesophageal junction adenocarcinoma.

Conditions

• Gastric Cancer (Diagnosis)
• Gastric Cancer (GC)
• Gastroesophageal Junction Adenocarcinoma

Interventions

Type	Name	Description
DRUG	Iparomlimab and Tuvonralimab (QL1706)	anti-PD-1/anti-CTLA-4 dual immunotherapy

Timeline

• Start date: 2026-06-01
• Primary completion: 2028-03-31
• Completion: 2029-06-30
• First posted: 2026-03-30
• Last updated: 2026-03-30